Categories
Anticancer Drugs Oncology Pharmacology Physiotherapy Ramucirumab

Ramucirumab (26)

In this article, we will discuss Ramucirumab (26). So, let’s get started.

Use in Specific Population 
Pregn*ncy Category C
Risk Summary
Based on its mechanism of action, Ramucirumab may cause fetal harm. Animal models link angiogenesis, VEGF and
VEGF Receptor 2 (VEGFR2) to critical aspects of female reproduction, embryo-fetal development, and post-natal
development. There are no adequate or well controlled studies of ramucirumab in pregn*nt women. If this drug is used
during pregnancy, or if the patient becomes pregn*nt while taking this drug, apprise the patient of the potential hazard to a
fetus.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Discover more from PT Master Guide

Subscribe now to keep reading and get access to the full archive.

Continue reading